Valuation: Island Pharmaceuticals Limited

Market Cap 96.23M 67.73M 60.66M 55.96M 50.64M 94.7M 6.45B 668M 266M 3.38B 254M 249M 10.69B P/E 2027 *
-6.91x
P/E 2028 * 0.25x
Enterprise Value 78.03M 54.92M 49.19M 45.38M 41.07M 76.79M 5.23B 541M 216M 2.74B 206M 202M 8.67B EV / Sales 2027 *
-
EV / Sales 2028 * 0.67x
Free-Float
52.32%
Yield 2027 *
-
Yield 2028 * -
1 week-4.41%
Current month-10.96%
1 month-16.67%
3 months-16.67%
6 months-17.72%
Current year-24.42%
1 week 0.3
Extreme 0.305
0.33
1 month 0.3
Extreme 0.295
0.4
Current year 0.3
Extreme 0.295
0.55
1 year 0.3
Extreme 0.295
0.63
3 years 0.05
Extreme 0.05
0.63
5 years 0.05
Extreme 0.05
0.63
10 years 0.05
Extreme 0.05
0.67
Manager TitleAgeSince
Chief Executive Officer - 2021-01-17
Director of Finance/CFO - -
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member - 2021-01-17
Director/Board Member - 2024-09-18
Chairman - 2025-07-01
Date Insider Type Main position Quantity % Market Cap. Importance
12/3/25 Exercice

Director

357,143 0.1403%
12/3/25 Exercice

Director

357,143 0.1403%
12/3/25 Exercice

Director

487,425 0.1914%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.41%-14.47%+392.43% 67.74M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.26%+12.91%+82.98% 55.53B
+1.75%+2.76%+12.38%+103.69% 53.03B
-1.43%-1.17%+26.27%+55.26% 45.99B
-0.48%-2.80%+18.01%+99.11% 42.45B
+0.82%+1.37%+227.94%+936.89% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.33%+3.60%+45.77%+186.12% 39.26B
Weighted average by Cap. -0.11%+3.13%+49.52%+160.79%

Financials

2027 *2028 *
Net sales - 643M 452M 405M 374M 338M 633M 43.09B 4.46B 1.78B 22.55B 1.7B 1.66B 71.42B
Net income -13.2M -9.29M -8.32M -7.68M -6.95M -12.99M -885M -91.59M -36.54M -463M -34.86M -34.12M -1.47B 375M 264M 236M 218M 197M 369M 25.11B 2.6B 1.04B 13.14B 990M 969M 41.63B
Net Debt -18.2M -12.81M -11.47M -10.58M -9.58M -17.91M -1.22B -126M -50.38M -638M -48.07M -47.05M -2.02B 335M 236M 211M 195M 176M 330M 22.46B 2.33B 928M 11.76B 885M 866M 37.24B
Projected Income Statement - Annual - Island Pharmaceuticals Limited
Logo Island Pharmaceuticals Limited
Island Pharmaceuticals Limited is an Australia-based drug repurposing company. The Company is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.
Employees
-
Date Price Change Volume
26-10-29 A$0.3250 0.00% 64,707
26-10-28 A$0.3250 +4.84% 34,205
26-10-27 A$0.3100 0.00% 38,586
26-10-26 A$0.3100 -4.62% 213,419
26-10-23 A$0.3250 +1.56% 108,817

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Island Pharmaceuticals Limited